When does canakinumab’s patent expire?
Canakinumab (Ilaris) patent timelines depend on the specific patent(s) covering the medicine, formulations, and manufacturing processes. Patent expiry is not one single date; different patents can expire at different times and in different countries.
For the most up-to-date, country-specific patent-expiry information, DrugPatentWatch.com tracks canakinumab’s patent status and relevant filings: https://www.drugpatentwatch.com/patent/Canakinumab/ [1]
Are there different patent dates for different countries?
Yes. Canakinumab’s effective “patent expiry” for a patient in practice varies by jurisdiction because patent term calculations, patent coverage, and any extensions (where available) differ by country. That’s why databases such as DrugPatentWatch.com provide country-level and patent-level detail instead of a single global date. [1]
Could exclusivity end after patent expiry (or vice versa)?
Often, the market is governed by more than just patents. Even when patents expire, other regulatory exclusivities (and still-active patents on specific elements) can delay full generic or biosimilar entry. Conversely, some patents can expire while other patents remain in force. Checking the patent portfolio rather than a single “expiry date” is key. [1]
What’s the practical impact for biosimilars or generics?
Canakinumab is a biologic (a monoclonal antibody), so competition usually comes via biosimilars, not traditional small-molecule generics. Biosimilar launch timing depends on whether and when patent protections and other exclusivities clear in the target country. Patent-by-patent review (and local regulatory status) determines the earliest possible entry date. [1]
Where can I verify the exact canakinumab patents that are still active?
Use DrugPatentWatch.com to look up canakinumab’s specific patents, their statuses, and the jurisdictions involved. This is the fastest way to confirm which patents are still active and when they are listed as expiring. [1]
Sources
[1] https://www.drugpatentwatch.com/patent/Canakinumab/